On September 3, 2024 BeyondSpring Inc. (NASDAQ: BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, reported that it will have an oral presentation on the final efficacy data of Plinabulin and docetaxel combination vs. docetaxel from Dublin-3 phase 3 study in EGFR wild-type 2L/3L non-small cell lung cancer (NSCLC) at the 2024 World Conference on Lung Cancer, on September 9, 2024 in San Diego, CA, and two poster presentations on Dublin-3 study safety outcome and 303 Study, the investigator-initiated study supported by Merck (known as MSD outside of the United States and Canada) in 2L/3L NSCLC who failed PD-1/PD-L1 inhibitors at European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2024, on September 14, 2024 in Barcelona, Spain (Press release, BeyondSpring Pharmaceuticals, SEP 3, 2024, View Source;utm_medium=rss&utm_campaign=beyondspring-announces-oral-presentation-at-the-2024-world-conference-on-lung-cancer-and-two-poster-presentations-during-esmo-congress-2024-showcasing-its-lead-anti-cancer-asset-plinabulin [SID1234646282]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation details are as follows:
2024 World Conference on Lung Cancer
Oral (OA08.04): Plinabulin/Docetaxel vs. Docetaxel in 2L/3L NSCLC after Platinum Regimens (DUBLIN-3): A Phase 3 Randomized Controlled Trial
Presenter: Trevor M. Feinstein, Principal investigator for Dublin-3 study, Piedmont Cancer Institute, Atlanta, GA, USA
Presentation Time: Monday, September 9, 2024, at 10:57AM to 11:07AM PDT
Session: OA08. The New Generation of Cytotoxics
ESMO Congress 2024
Poster (1358P): Plinabulin/Docetaxel Versus Docetaxel in Survival Benefits of 2L/3L EGFR Wild-Type NSCLC after Platinum Regimens (DUBLIN-3): a Randomized Phase 3 Trial
Presenter: Trevor M. Feinstein
Presentation Time: Saturday, September 14, 2024, at 9AM to 6:30PM CEST
Location: Hall 3, Av. Joan Carles I, 64
08908 L’hospitalet de Llobregat
Barcelona, Spain
Session: NSCLC, metastatic
Poster (1330P): Phase 2 Study of Pembrolizumab (Pemb) plus Plinabulin (Plin) and Docetaxel (Doc) for Patients (pts) with Metastatic NSCLC after Failure on First-line Immune Checkpoint Inhibitor Alone or Combination Therapy: Initial Efficacy and Safety Results on Immune Re-sensitization
Presenter: Yan Xu, Investigator, Peking Union Medical College Hospital, Beijing, China
Presentation Time: Saturday, September 14, 2024, at 9AM to 6:30PM CEST
Location: Hall 3, Av. Joan Carles I, 64
08908 L’hospitalet de Llobregat
Barcelona, Spain
Session: NSCLC, metastatic